B2B Software Technologies Limited is a **Microsoft Gold Certified Partner** with over **25 years** of domain expertise in business consulting, software development, and IT implementation. The company has executed more than **200 client engagements** globally, evolving from a legacy financial entity into a specialized provider of **Enterprise Resource Planning (ERP)** and **Healthcare IT** solutions. --- ### **Core Business Verticals & Proprietary Product Suite** The company operates through two established divisions and is currently scaling a third focused on next-generation technologies. #### **1. Enterprise Technology (Microsoft Dynamics Ecosystem)** B2B is a leading provider of **Microsoft Dynamics ERP** (NAV, AX, and D365 Business Central) implementations. To differentiate from generic service providers, the company develops proprietary, Microsoft-certified add-ons. * **B2B LIFT:** A flagship **Pharma Vertical Solution** certified for **GMP (Good Manufacturing Practice)** compliance. * **B2B Quality Assurance:** A globally recognized QA product sold through a reseller network of **200+ partners** in **15+ countries**. * **B2B HR & Payroll:** A localized extension for **D365** customized for complex regulatory environments in the **UAE, Egypt, Qatar, Nigeria, and Ethiopia**. * **Specialized Modules:** Includes **Plant Maintenance**, **Budget Control**, and industry-specific platforms for **Apparel, Construction, and Tower Manufacturing**. #### **2. Healthcare Division (GeniusDoc)** This division focuses on clinical workflow optimization and patient management, primarily in the **USA and the Bahamas**. * **GeniusDoc EMR:** A certified Electronic Medical Record platform featuring **ONC-ACB, Surescripts, and MU certifications**. * **Interoperability:** Fully interfaced with **EPIC EMR, Quest, LabCorp**, and over **60,000 pharmacies**. * **Comprehensive Modules:** Includes Practice Management (**PM**), Revenue Cycle Management (**RCM**), **Telehealth**, and **GD Mobile**. * **Clinical Features:** Electronic Prescription for Controlled Substances (**EPCS**) and integrated payment workflows via **TransFirst**. #### **3. Emerging & AI Technologies (New Growth Engine)** Launched in **September 2025** with an initial **₹1 crore** investment, this division focuses on high-margin digital transformation. * **AI & Machine Learning:** Development of **Agentic Chatbots**, **NLP-based** voice-to-text for physicians, and predictive analytics for oncology. * **Cloud & Security:** Specialized services in **Azure/AWS migrations**, **Cybersecurity**, and **HIPAA compliance**. --- ### **Strategic Pivot: The Oncology & AI Roadmap** The company is aggressively shifting toward **Precision Medicine** and **Oncology Analytics** to capture higher economic value. * **The AVCC Contract:** B2B secured a **5-year** development contract with **Antelope Valley Cancer Center (AVCC)**, USA. * **Value:** **USD 1,000,000** (approx. **₹8.65 crores**), with a potential ceiling of **USD 1,500,000**. * **Objective:** Development of **20 AI-based modules** for oncology digital transformation. * **Inorganic Growth:** The Board is exploring acquiring **minority stakes** in **Ambulatory Cancer Centers** in the USA to deploy idle funds and deepen industry integration. * **MoA Amendment:** The company recently amended its **Memorandum of Association** to permit direct investments and joint ventures in healthcare facilities. --- ### **Financial Performance & Capital Structure** B2B maintains a **debt-free balance sheet** with a **Debt-to-Equity Ratio of 0**. | Financial Metric (Standalone) | FY 2024-25 | FY 2023-24 | | :--- | :--- | :--- | | **Total Revenue (incl. Other Income)** | **₹25.63 Crores** | **₹21.66 Crores** | | **Profit Before Tax (PBT)** | **₹3.26 Crores** | **₹2.40 Crores** | | **Net Profit (FY 2025-26 Projection)** | **~₹2.51 Crores** | - | | **Foreign Exchange Earnings** | **₹7.55 Crores** | **₹6.25 Crores** | **Liquidity Position (as of March 31, 2026):** * **Fixed Deposits:** **₹257.22 Lakhs** * **Current Accounts:** **₹207.03 Lakhs** * **Total Cash & Equivalents:** **₹542.41 Lakhs** --- ### **Corporate Actions & Shareholder Value** The company has implemented several measures to improve stock liquidity and reward long-term investors: * **Bonus Issue:** A **1:2 bonus issue** was allotted on **April 2, 2026**. * **Stock Split:** Recommended sub-division of shares from **₹10** to **₹2** face value in **November 2025**. * **Capital Expansion:** Authorized share capital increased from **₹12 Crores** to **₹18 Crores**. * **Dividends:** Declared an interim dividend of **₹1 per share** in **January 2026**. * **Promoter Reclassification:** Successfully reclassified specific former promoters to the **"Public Group"** in **October 2024**, resulting in a current promoter holding of **59.84%**. --- ### **Operational Structure & Human Capital** * **Headquarters:** **Hyderabad, India**, with a material subsidiary, **B2B Softech Inc**, in the **USA**. * **Workforce:** **109 employees** (91 male, 18 female) as of March 2025. * **Incentive Alignment:** Transitioning from the **ESOP-2024 Scheme** (which granted **2,50,325 options**) to a **Restricted Stock Unit (RSU) Scheme** to better retain top-tier engineering talent. * **Global Reach:** Active implementations across **Singapore, Australia, Malaysia, South Africa, UAE, and Vietnam**. --- ### **Risk Profile & Mitigation Strategies** | Risk Category | Specific Challenge | Mitigation Strategy | | :--- | :--- | :--- | | **Market Competition** | Pricing pressure from new Microsoft Dynamics entrants. | Focus on **Proprietary IP** and vertical-specific "add-ons" that command higher margins. | | **Regulatory Compliance** | Past SEBI penalties for committee composition and insider trading disclosure delays. | Appointment of new **Independent Directors** and Dr. Avinash Yaramati as Chairman to strengthen governance. | | **Legacy Financials** | Carry-forward losses from **pre-2000 NBFC activities** impact remuneration limits. | Utilizing **Schedule V** of the Companies Act for managerial pay; focusing on software profit growth to offset legacy drag. | | **Market Consolidation** | US hospital groups acquiring private practices, potentially displacing **GeniusDoc**. | Enhancing interoperability with major systems like **EPIC** to remain a viable "best-of-breed" solution. | | **Credit Risk** | Exposure to trade receivables from international subsidiaries. | Strict creditworthiness checks and maintaining high levels of liquid funds in reputable banks. | ### **Investment Outlook** B2B Software Technologies is transitioning from a traditional IT service provider to an **IP-led AI and Healthcare technology firm**. With a **debt-free status**, a significant **USD-denominated AI contract**, and a robust **Microsoft partnership**, the company is positioned to leverage the digital transformation of the global oncology market. However, investors should monitor the company's ability to maintain **SEBI compliance** and successfully execute its **RSU-based talent retention** strategy.